Variable/category | Gene expression-based risk group | χ2 | P value | |
---|---|---|---|---|
GR group n (%) | PR group n (%) | |||
Total number of patients | 362 (95.8) | 16 (4.2) | Â | Â |
Age (year) | ||||
 ≥ 10 | 41 (11.3) | 2 (12.5) | 6.75 | 0.031 |
 1–10 | 316 (87.3) | 12 (75.0) |  |  |
 < 1 | 5 (1.4) | 2 (12.5) |  |  |
Gender | ||||
 Male | 229 (63.3) | 9 (56.2) | 0.32 | 0.570 |
 Female | 133 (36.7) | 7 (43.8) |  |  |
WBC (× 109/l) | ||||
 ≥ 50 × 109/l | 72 (19.9) | 12 (75.0) | 23.83 | < 0.001 |
 < 50 × 109/l | 290 (80.1) | 4 (25.0) |  |  |
Immunophenotype | ||||
 T-ALL | 29 (8.0) | 7 (43.8) | 18.76 | < 0.001 |
 B-ALL | 333 (92.0) | 9 (56.2) |  |  |
Chromosome abnormalities in B-ALL | ||||
 BCR-ABL1 | 20 (6.0) | 6 (66.7) | 31.22 | < 0.001 |
 E2A-PBX1 | 27 (8.1) | 0 |  |  |
 TEL-AML1 | 109 (32.7) | 0 |  |  |
 MLL rearrangements | 8 (2.4) | 2 (22.2) |  |  |
 Hyperdiploid > 50 | 107 (32.1) | 0 |  |  |
 Other B-ALL | 62 (18.6) | 1 (11.1) |  |  |
Prednisone response | ||||
 Good | 351 (97.0) | 11 (68.8) | 23.53 | < 0.001 |
 Poor | 11 (3.0) | 5 (31.2) |  |  |
MRD at day 33 | ||||
 Positive | 12 (3.6) | 3 (27.3) | 9.04 | 0.003 |
 Negative | 317 (96.4) | 8 (72.7) | ||
 Not evaluated | 33 | 5 | ||
MRD at day 78 | ||||
 Positive | 7 (2.2) | 2 (22.2) | 6.69 | 0.010 |
 Negative | 311 (97.8) | 7 (77.8) | ||
 Not evaluated | 44 | 7 | ||
Clinical risk group | ||||
 Standard risk | 87 (24.0) | 0 | 30.83 | < 0.001 |
 Intermediate risk | 230 (63.5) | 4 (25.0) | ||
 High risk | 45 (12.4) | 12 (75.0) | ||
Outcome | ||||
 Eventa | 36 (9.9) | 13 (81.3) | 62.88 | < 0.001 |
 Remission | 326 (90.1) | 3 (18.7) |  |  |